Value202020212022202320242025TTMSelling/general/admin expenses3.91 M4.31 M5.07 M6.31 M6.32 M3.14 M—Research & development18.17 M19.47 M17.63 M12.52 M9.15 M8.09 M—Operating income22.93 M24.78 M29.16 M49.69 M20.41 M10.29 M—Non-Operating Income, Total———————Interest expense, net of interest capitalized———————Non-Operating Income, excl. Interest Expenses———————Unusual income/expense———————Pretax income21.53 M24.33 M27.69 M49.59 M13.16 M10.47 M—Equity in earnings———————Taxes000000—Non-controlling/minority interest—————6 M—After tax other income/expense———————Net income before discontinued operations30.02 M27.05 M24.95 M60.61 M9.22 M2.03 M—Discontinued operations———————Net income30.02 M27.05 M24.95 M60.61 M9.22 M2.03 M—Dilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders———————Basic earnings per share (Basic EPS)———————Diluted earnings per share (Diluted EPS)———————Average basic shares outstanding———————Diluted shares outstanding———————EBITDA———————EBIT———————Cost of revenue———3.69 M9.26 M230 K—Other cost of goods sold———————Depreciation & amortization (cash flow)864 K660 K615 K583 K431 K495 K—
BioLineRx Ltd - American Depositary Shares
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.